FibroScan Validity in PSC
FibroScan (vibration-controlled transient elastography/VCTE) is a valid and reliable tool for assessing liver fibrosis in PSC patients, with strong correlation to histological fibrosis stages and excellent prognostic value for clinical outcomes including transplant-free survival. 1
Diagnostic Performance for Fibrosis Staging
VCTE demonstrates high diagnostic accuracy for detecting advanced fibrosis and cirrhosis in PSC:
- For extensive fibrosis (≥F3): Cut-off of 9.6 kPa with diagnostic accuracy >0.80 1
- For cirrhosis (F4): Cut-off of 14.4 kPa with diagnostic accuracy >0.80 1
- For advanced fibrosis: Cut-off of 9.5 kPa supports diagnosis in compensated patients with normal bilirubin and without high-grade stenosis 1
The most robust validation comes from a study showing VCTE independently correlates with histological fibrosis stage, with areas under ROC curves of 0.83 for severe fibrosis and 0.88 for cirrhosis 2. An earlier multicenter study demonstrated even higher performance with AUROCs of 0.95 for F≥3 and 0.96 for F4 3.
Prognostic Value for Clinical Outcomes
Both baseline values and longitudinal changes in liver stiffness measurements strongly predict mortality and transplantation risk:
- Low-risk threshold: Values <6.5 kPa associated with very low event rates 1
- High-risk threshold: Values >9.9 kPa associated with worse outcomes 1
- Optimal prognostic cut-off: 13.1 kPa differentiates low and high-risk groups for transplant-free survival after 3 years of follow-up 1
The 2026 prospective FICUS cohort study (the most recent high-quality evidence) validated these findings in 538 patients followed for median 60.7 months. Five-year transplant-free survival rates were stratified by baseline LSM: 93.9% for 2.5-<10 kPa, 78.1% for 10-<15 kPa, and 46.0% for ≥15 kPa 4. Importantly, each 1-kPa/year increment in LSM was associated with 18% increased risk of death or transplantation 4.
Guideline Recommendations
The 2022 EASL Clinical Practice Guidelines explicitly recommend:
- Non-invasive assessment of fibrosis using VCTE should be considered in PSC patients (Grade B2) 1
- VCTE is one of only 5 candidates identified by consensus for measuring disease progression 1
- The 2019 British Society of Gastroenterology guidelines acknowledge that while evidence is still evolving, non-invasive markers including transient elastography show strong correlation with histological fibrosis and prognostic significance 5
Additional Clinical Utility
VCTE is useful for predicting high-risk varices in PSC patients with cirrhosis. Baveno-VI criteria (LSM <20 kPa and platelets >150×10⁹/L) had 0% false negative rate, safely avoiding 30% of unnecessary endoscopies 1.
Important Caveats and Limitations
Cholestasis from untreated dominant biliary strictures influences liver stiffness assessment 1. Therefore:
- VCTE should be interpreted in compensated patients with normal bilirubin
- Presence of high-grade stenosis may confound results
- Technical failure occurs in approximately 5.9% of cases 3
VCTE performs better than other non-invasive markers (APRI, FIB-4, Mayo risk score) for differentiating significant or severe fibrosis 2, though the Enhanced Liver Fibrosis (ELF) test is also validated and can complement VCTE for risk stratification 1.
Practical Application
For PSC monitoring:
- Baseline VCTE establishes fibrosis stage and prognosis
- Serial measurements track disease progression (significant positive slope indicates worse outcomes 4)
- Values <6.5 kPa: Excellent prognosis, low monitoring intensity
- Values 6.5-10 kPa: Intermediate risk, annual monitoring
- Values >10 kPa: High risk, closer surveillance and transplant evaluation consideration
- Values >15 kPa: Very high risk, expedited transplant evaluation